russ2000_2_0189|CYCN|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
russ2000_2_0189|CYCN|1|Cyclerion Therapeutics Inc Total Current Assets (Quarterly) (USD)|Cyclerion Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Cyclerion Therapeutics Inc Inventories (Quarterly) (USD)|Cyclerion Therapeutics Inc Net PP&E (Quarterly) (USD)|Cyclerion Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Liabilities (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Deposits (Quarterly) (USD)|Cyclerion Therapeutics Inc Book Value (Quarterly) (USD)|Cyclerion Therapeutics Inc Retained Earnings (Quarterly) (USD)|Cyclerion Therapeutics Inc Treasury Stock (Quarterly) (USD)|Cyclerion Therapeutics Inc EV to Revenues|Cyclerion Therapeutics Inc EV to Earnings|Cyclerion Therapeutics Inc EV to Free Cash Flow|Cyclerion Therapeutics Inc EV to Assets (Quarterly)|Cyclerion Therapeutics Inc PS Ratio|Cyclerion Therapeutics Inc PE Ratio|Cyclerion Therapeutics Inc Price to Book Value|Cyclerion Therapeutics Inc PEG Ratio|Cyclerion Therapeutics Inc Debt to Equity Ratio|Cyclerion Therapeutics Inc Dividend Yield|Cyclerion Therapeutics Inc Shareholder Yield (TTM)|Cyclerion Therapeutics Inc Percent of Shares Outstanding Short|Cyclerion Therapeutics Inc Total Receivables (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Payables (Quarterly) (USD)|Cyclerion Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Cyclerion Therapeutics Inc Return on Invested Capital|Cyclerion Therapeutics Inc Quality Ratio Score|Cyclerion Therapeutics Inc Momentum Score|Cyclerion Therapeutics Inc Beta (1Y)|Cyclerion Therapeutics Inc Sustainable Growth Rate (TTM)|Cyclerion Therapeutics Inc Institutional Investor Ownership Percentage|Cyclerion Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Cyclerion Therapeutics Inc Total Employees (Annual)|Cyclerion Therapeutics Inc EPS Diluted (Quarterly) (USD)|Cyclerion Therapeutics Inc Shares Outstanding|Cyclerion Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Cyclerion Therapeutics Inc Ordinary Shares Number (Quarterly)|Cyclerion Therapeutics Inc Payout Ratio|Cyclerion Therapeutics Inc Quick Ratio (Quarterly)|Cyclerion Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Cyclerion Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Cyclerion Therapeutics Inc Effective Tax Rate (TTM)|Cyclerion Therapeutics Inc Return on Equity|Cyclerion Therapeutics Inc Net Income (TTM) (USD)|Cyclerion Therapeutics Inc Revenue (TTM) (USD)|Cyclerion Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Cyclerion Therapeutics Inc Revenue (Quarterly) (USD)|Cyclerion Therapeutics Inc Gross Profit (Quarterly) (USD)|Cyclerion Therapeutics Inc SG&A Expense (Quarterly) (USD)|Cyclerion Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Cyclerion Therapeutics Inc Net Income (Quarterly) (USD)|Cyclerion Therapeutics Inc Net Interest Income (Quarterly) (USD)|Cyclerion Therapeutics Inc Price (USD)|Cyclerion Therapeutics Inc Total Return Price (USD)|Cyclerion Therapeutics Inc Enterprise Value (USD)|Cyclerion Therapeutics Inc 30-Day Average Daily Volume|Cyclerion Therapeutics Inc 1 Year Price Returns (Daily)||
russ2000_2_0189|CYCN|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
russ2000_2_0189|CYCN|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
russ2000_2_0189|CYCN|5|91.1666666667|91.1666666667||91.1666666667||91.1666666667|91.1666666667|91.1666666667||91.1666666667|91.1666666667||1.43055555556|91|1.43734643735|91.5|1.43055555556||1.44144144144||91.5|1.44088669951|91|15.2571428571|91.1666666667|91.1666666667|91.1666666667|91||30.6|30.5|91|30.5|91.3333333333|365|91.3333333333|31.3125||91.1666666667|91|91.5|91.3333333333|91.375||91|91.1666666667|91||91.5||91.3333333333|91.3333333333|91.3333333333|91.375|1.44088669951|1.44088669951|1.43734643735|1.44031830239|1.43137254902||
russ2000_2_0189|CYCN|6|6|6||6||6|6|6||6|6||144|1|407|4|144||333||4|406|1|35|6|6|6|1||5|6|1|2|9|1|9|16||6|1|4|9|8||1|6|1||4||9|9|9|8|406|406|407|377|153||
russ2000_2_0189|CYCN|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
russ2000_2_0189|CYCN|201803||||||||||||||||||||||||||||||||||27.304||-0.926||||||-0.926|||||||||3.769|-25.283|-25.283||||||||
russ2000_2_0189|CYCN|201806||||||||||||||||||||||||||||||||||27.304||-1.0907||||||-1.0907|||||||||7.53|-29.781|-29.781||||||||
russ2000_2_0189|CYCN|201809||||||||||||||||||||||||||||||||||27.304||-1.0726||||||-1.0726|||||||||7.787|-29.286|-29.286||||||||
russ2000_2_0189|CYCN|201812|0.879|||6.497||17.846|17.846|||-10.445||||||||||||||||2.781||||||||27.3045|140|-1.1318|||27.4112|||-1.1318||||-115.252|||||8.45|-30.902|-30.902||||||||
russ2000_2_0189|CYCN|201903|0.939|||8.815||17.525|17.473|0.052||-7.752|||||-5.6886|||||||||4.9617||5.671||||||||27.38||-1.37|27.3045||27.4017|||-1.37||||-127.35|||||10.977|-37.381|-37.381||21.03|21.03|574.2136|181996.7||15.23|13.95
russ2000_2_0189|CYCN|201906|144.693|141.03||83.084||94.313|21.916|72.397||141.19|-32.254||||-1.5196|0.7339|||1.8036|||||3.3315|1.857|8.783||||||||27.393||-1.18|27.4112||27.4112||6.5198|-1.18|-175|||-129.823|||1.628||8.923|-32.254|-32.254|0.8|11.45|11.45|172.8282|235103.3||9.29|9.51
russ2000_2_0189|CYCN|201909|120.706|117.034||81.272||90.507|19.096|71.411||119.197|-59.572||||-1.9321|1.0295|||2.793|||||4.4921|1.44|5.005||||||||27.434||-1|27.4684||27.4684||6.2041|-1||||-127.854|||1.398||7.119|-27.317|-27.317|0.699|12.12|12.12|215.883|120432.1333||2.39|1.85
russ2000_2_0189|CYCN|201912|101.197|94.895||79.75||88.749|18.249|70.5||97.729|-85.627||||0.1817|-0.1063|||0.7681|||||2.8119|1.474|3.311||||||||27.38|94|-0.95|27.5981||27.5981||5.2808|-0.95||||-123.007|||1.481||7.385|-26.055|-26.055|0.531|2.72|2.72|-19.8282|900320.8||3.28|4.28
russ2000_2_0189|CYCN|202003|70.126|67.096||63.854||58.49|11.435|47.055||81.54|-105.855||1.1691|-0.061|-0.0623|0.0461|13.1847||0.902||||-237.9318|5.4076|1.026|1.522||-96.3062||1|-0.2716|-122.5434||27.669||-0.73|27.7549||27.7549||5.9573|-0.8064|||-122.5434|-105.854|5.521||1.014||6.891|-20.228|-20.228|0.361|2.65|2.65|6.4545|545970.9667|-87.399|3.87|3.98
russ2000_2_0189|CYCN|202006|59.562|56.462||62.093||61.937|15.645|46.292||66.101|-125.389||24.0599|-1.1992|-1.2182|0.8723|35.0991||2.4907||0.0531||-0.4263|3.7434|0.751|2.588||-91.4394||1|1.7627|-92.0739|96.224|27.791||-0.7|27.8577||27.8577||3.657|-0.7|||-92.0739|-93.134|4.642||0.749||6.627|-19.534|-19.534|0.138|5.91|5.91|111.686|278370.5667|-48.3843|3.82|6.82
russ2000_2_0189|CYCN|202009|||||||||||||33.0206||-1.6719||36.1087||3.12|||||2.765||||||3|2.1254||91.605||||||||||||||||||||||6.08|6.08|153.2818|255931.0667|-49.835|2.64|